162 related articles for article (PubMed ID: 38166929)
1. Enhancing immune responses of ESC-based TAA cancer vaccines with a novel OMV delivery system.
Jin M; Huo D; Sun J; Hu J; Liu S; Zhan M; Zhang BZ; Huang JD
J Nanobiotechnology; 2024 Jan; 22(1):15. PubMed ID: 38166929
[TBL] [Abstract][Full Text] [Related]
2. Engineered Bacterial Outer Membrane Vesicles with Lipidated Heterologous Antigen as an Adjuvant-Free Vaccine Platform for Streptococcus suis.
Li Q; Zhou G; Fei X; Tian Y; Wang S; Shi H
Appl Environ Microbiol; 2023 Mar; 89(3):e0204722. PubMed ID: 36809058
[TBL] [Abstract][Full Text] [Related]
3. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
[TBL] [Abstract][Full Text] [Related]
4. Outer membrane vesicles engineered to express membrane-bound antigen program dendritic cells for cross-presentation to CD8
Schetters STT; Jong WSP; Horrevorts SK; Kruijssen LJW; Engels S; Stolk D; Daleke-Schermerhorn MH; Garcia-Vallejo J; Houben D; Unger WWJ; den Haan JMM; Luirink J; van Kooyk Y
Acta Biomater; 2019 Jun; 91():248-257. PubMed ID: 31003032
[TBL] [Abstract][Full Text] [Related]
5. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
6. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
Yu X; Long Y; Chen B; Tong Y; Shan M; Jia X; Hu C; Liu M; Zhou J; Tang F; Lu H; Chen R; Xu P; Huang W; Ren J; Wan Y; Sun J; Li J; Jin G; Gong L
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253000
[TBL] [Abstract][Full Text] [Related]
7. A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx).
Guo L; Overholser J; Darby H; Ede NJ; Kaumaya PTP
Oncoimmunology; 2022; 11(1):2127691. PubMed ID: 36211807
[TBL] [Abstract][Full Text] [Related]
8. Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors.
Nagato T; Lee YR; Harabuchi Y; Celis E
Clin Cancer Res; 2014 Mar; 20(5):1223-34. PubMed ID: 24389326
[TBL] [Abstract][Full Text] [Related]
9. Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via Plug-and-Display technology.
Cheng K; Zhao R; Li Y; Qi Y; Wang Y; Zhang Y; Qin H; Qin Y; Chen L; Li C; Liang J; Li Y; Xu J; Han X; Anderson GJ; Shi J; Ren L; Zhao X; Nie G
Nat Commun; 2021 Apr; 12(1):2041. PubMed ID: 33824314
[TBL] [Abstract][Full Text] [Related]
10. Engineered outer membrane vesicle is potent to elicit HPV16E7-specific cellular immunity in a mouse model of TC-1 graft tumor.
Wang S; Huang W; Li K; Yao Y; Yang X; Bai H; Sun W; Liu C; Ma Y
Int J Nanomedicine; 2017; 12():6813-6825. PubMed ID: 28979120
[TBL] [Abstract][Full Text] [Related]
11. Display of Recombinant Proteins on Bacterial Outer Membrane Vesicles by Using Protein Ligation.
van den Berg van Saparoea HB; Houben D; de Jonge MI; Jong WSP; Luirink J
Appl Environ Microbiol; 2018 Apr; 84(8):. PubMed ID: 29439988
[TBL] [Abstract][Full Text] [Related]
12. Human B Cell Responses to Dominant and Subdominant Antigens Induced by a Meningococcal Outer Membrane Vesicle Vaccine in a Phase I Trial.
Rollier CS; Dold C; Marsay L; Linder A; Green CA; Sadarangani M; Norheim G; Derrick JP; Feavers IM; Maiden MCJ; Pollard AJ
mSphere; 2022 Feb; 7(1):e0067421. PubMed ID: 35080470
[TBL] [Abstract][Full Text] [Related]
13. Bacterial Outer Membrane Vesicles Presenting Programmed Death 1 for Improved Cancer Immunotherapy
Li Y; Zhao R; Cheng K; Zhang K; Wang Y; Zhang Y; Li Y; Liu G; Xu J; Xu J; Anderson GJ; Shi J; Ren L; Zhao X; Nie G
ACS Nano; 2020 Dec; 14(12):16698-16711. PubMed ID: 33232124
[TBL] [Abstract][Full Text] [Related]
14. Robust Immune Response Induced by
Barbosa MMF; Kanno AI; Barazzone GC; Rodriguez D; Pancakova V; Trentini M; Faquim-Mauro EL; Freitas AP; Khouri MI; Lobo-Silva J; Goncalves VM; Schenkman RPF; Tanizaki MM; Boraschi D; Malley R; Farias LP; Leite LCC
Int J Nanomedicine; 2021; 16():7153-7168. PubMed ID: 34712047
[TBL] [Abstract][Full Text] [Related]
15. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
[TBL] [Abstract][Full Text] [Related]
16. CD4
Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of
Croia L; Boscato Sopetto G; Zanella I; Caproni E; Gagliardi A; Tamburini S; König E; Benedet M; Di Lascio G; Corbellari R; Grandi A; Tomasi M; Grandi G
Membranes (Basel); 2023 Nov; 13(11):. PubMed ID: 37999368
[TBL] [Abstract][Full Text] [Related]
18. Bacterial outer membrane vesicle-based cancer nanovaccines.
Gao X; Feng Q; Wang J; Zhao X
Cancer Biol Med; 2022 Sep; 19(9):1290-300. PubMed ID: 36172794
[TBL] [Abstract][Full Text] [Related]
19. An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial.
Grauslund JH; Holmström MO; Martinenaite E; Lisle TL; Glöckner HJ; El Fassi D; Klausen U; Mortensen REJ; Jørgensen N; Kjær L; Skov V; Svane IM; Hasselbalch HC; Andersen MH
Front Immunol; 2023; 14():1117466. PubMed ID: 36911725
[TBL] [Abstract][Full Text] [Related]
20. Synergistic Protective Activity of Tumor-Specific Epitopes Engineered in Bacterial Outer Membrane Vesicles.
Grandi A; Tomasi M; Zanella I; Ganfini L; Caproni E; Fantappiè L; Irene C; Frattini L; Isaac SJ; König E; Zerbini F; Tavarini S; Sammicheli C; Giusti F; Ferlenghi I; Parri M; Grandi G
Front Oncol; 2017; 7():253. PubMed ID: 29164053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
